The fill finish manufacturing market was valued at US$ 6,129.03 million in 2019 and is projected to reach US$ 12,547.23 million by 2027; it is expected to grow at a CAGR of 9.6% from 2020 to 2027.
Fill-finish is the final manufacturing step (and perhaps the most critical) in the overall drug manufacturing process. It comes after upstream bioprocessing and also takes place after downstream purification. Fill finish manufacturing involves aseptically filling of biological drugs or medicines in any form, such as sterile liquid, powder, and suspension, in vials, ampoules, bottles syringes, and cartridges.
Request For Exclusive Sample PDF of this Report @ https://www.theinsightpartners.com/sample/TIPRE00018228/
Competitive fill finish manufacturing Market:
The fill finish manufacturing market, based on product, is segmented into consumables and instruments. The consumables segment is further segmented into prefilled syringes, vials, cartridges, and other consumables. In 2019, the consumables segment accounted for a larger share of the market and is expected to register a higher CAGR during the forecast period. Growth of this segment is attributed to high replacement rate compared with that of the instruments segment, rising adoption of prefilled syringes, wide applications of vials in lyophilization, and increasing fill-finish outsourcing.
The scope of the fill finish manufacturing market includes the product, end user and region. The market for fill finish manufacturing is analyzed based on regions such as North America, Europe, Asia Pacific, Middle East & Africa, and South and Central America. The report offers insights and in-depth analysis of the fill finish manufacturing market emphasizing on various parameters such as market trends, technological advancements, market dynamics, and competitive landscape analysis of leading market players across the globe.
Biologics constitute a majority of the top-selling drugs, and they presently represent one of the fastest-growing pharmaceutical industry segments. Since the launch of recombinant protein-based therapies, ~30 years back, the overall biologics market has grown at an annual rate of more than 12%. Fill finish is the final step in the production process, and it is one of the most crucial stages of drug manufacturing. Biologics require special procedures and equipment for fill finish operations to ensure product integrity and safety. Thus, the rise in demand for biologics has resulted in an equivalent need for flexible aseptic fill finish technologies.
COVID-19 pandemic has become the most significant challenge across the world. However, the pandemic has brought several growth opportunities to the pharmaceutical and biopharmaceutical companies to strengthen their R&D for vaccine formulation against the coronavirus. Moderna, Inc. and Catalent, Inc. announced a collaboration for large-scale, commercial fill-finish manufacturing of Moderna’s mRNA-based COVID-19 vaccine candidate (mRNA-1273) at Catalent’s biologics facility in Bloomington.
Interested in Purchasing this Report? Click here @ https://www.theinsightpartners.com/buy/TIPRE00018228/
Note: If you have any special requirements, please let us know and we will offer you the report as you want.
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.